GPX4 and cancer: In summary, CeO2-based nanozymes could be clinically translated as novel antioxidants and synergetic GPX4 activators to inhibit cardiomyocyte ferroptosis, thereby mitigating DIC in cancer patients, while improving their prognosis and quality of life.